Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric B Haura

Showing results (191-200 of 201) with videos related to

Pageof 21
Sort By:
Nature Communications|August 10, 2019
Proteogenomic landscape of squamous cell lung cancerPaul A Stewart, Eric A Welsh, Robbert J C Slebos, et al.
The Journal of Thoracic and Cardiovascular Surgery|November 11, 2022
Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancerValerie W Rusch, Alan Nicholas, G Alexander Patterson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 18, 2025
Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS StudyMatthew G Krebs, Byoung Chul Cho, Sandrine Hiret, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2021
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I StudyKeunchil Park, Eric B Haura, Natasha B Leighl, et al.
Cancer Discovery|February 14, 2012
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancerPeter S Hammerman, Martin L Sos, Alex H Ramos, et al.
Plos One|June 9, 2017
Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization studyRobert Carreras-Torres, Mattias Johansson, Philip C Haycock, et al.
Carcinogenesis|October 24, 2017
Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian populationYafang Li, Xiangjun Xiao, Younghun Han, et al.
Oncotarget|April 9, 2019
Genetic interaction analysis among oncogenesis-related genes revealed novel genes and networks in lung cancer developmentYafang Li, Xiangjun Xiao, Yohan Bossé, et al.
Nature Communications|May 13, 2020
Protein-altering germline mutations implicate novel genes related to lung cancer developmentXuemei Ji, Semanti Mukherjee, Maria Teresa Landi, et al.
Nature Communications|August 15, 2018
Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer riskXuemei Ji, Yohan Bossé, Maria Teresa Landi, et al.
Pageof 21

Showing results (191-200 of 201) with videos related to

Sort By:
Pageof 21
Nature Communications|August 10, 2019
Proteogenomic landscape of squamous cell lung cancerPaul A Stewart, Eric A Welsh, Robbert J C Slebos, et al.
The Journal of Thoracic and Cardiovascular Surgery|November 11, 2022
Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancerValerie W Rusch, Alan Nicholas, G Alexander Patterson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 18, 2025
Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS StudyMatthew G Krebs, Byoung Chul Cho, Sandrine Hiret, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2021
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I StudyKeunchil Park, Eric B Haura, Natasha B Leighl, et al.
Cancer Discovery|February 14, 2012
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancerPeter S Hammerman, Martin L Sos, Alex H Ramos, et al.
Plos One|June 9, 2017
Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization studyRobert Carreras-Torres, Mattias Johansson, Philip C Haycock, et al.
Carcinogenesis|October 24, 2017
Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian populationYafang Li, Xiangjun Xiao, Younghun Han, et al.
Oncotarget|April 9, 2019
Genetic interaction analysis among oncogenesis-related genes revealed novel genes and networks in lung cancer developmentYafang Li, Xiangjun Xiao, Yohan Bossé, et al.
Nature Communications|May 13, 2020
Protein-altering germline mutations implicate novel genes related to lung cancer developmentXuemei Ji, Semanti Mukherjee, Maria Teresa Landi, et al.
Nature Communications|August 15, 2018
Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer riskXuemei Ji, Yohan Bossé, Maria Teresa Landi, et al.
Pageof 21